HUNTER CAPITAL RTO 1 AB (PUBL)
NNGM:HCRTO10.87
SEK
-0.11
(-11.22%)
ISIN
SE0026526352
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Jacob Alexander Eriksson
- Sector
- Finance
- Industry
- Financial conglomerates
- Address
- Stockholm Sweden
- IPO Date
- Mar 6, 2026
- Similar Companies
- Business
- Hunter Capital RTO 1 AB (publ) is a Sweden-based special purpose acquisition vehicle and public shell company dedicated to identifying, acquiring, and merging with private growth-stage enterprises through reverse takeover (RTO) transactions. The company provides private operating enterprises with an accelerated, structured, and cost-effective pathway to access public capital markets by utilizing its publicly traded shares as acquisition consideration. Its core business activities and structural offerings encompass reverse takeover transaction structuring and execution; public listing vehicle facilitation on Nordic growth equity exchanges; equity-for-share acquisition mechanisms; public capital market access and bridge financing coordination for target entities; regulatory listing compliance and transition frameworks; and post-combination corporate integration platforms. The company primarily targets unlisted growth businesses across the Nordic region and broader Europe, with a strategic focus on high-growth sectors including biotechnology, life sciences, and technology. Established in August 2025 and headquartered in Stockholm, Sweden, Hunter Capital RTO 1 AB operates within the capital markets and financial services industry and is affiliated with the Swedish investment entity Hunter Capital AB. In March 2026, the company successfully completed its initial public listing on the Spotlight Stock Market under the ticker symbol HCRTO1. In recent operational developments, Hunter Capital RTO 1 AB entered into a non-binding letter of intent in March 2026 to execute a reverse takeover of ResoTher Pharma A/S, a clinical-stage Danish biopharmaceutical company focused on peptide-based therapeutics for cardiovascular and inflammatory disorders. In late 2026, the transaction advanced through key milestones, including the completion of an approximately SEK 14.8 million bridge financing round by ResoTher Pharma and the reporting of positive Phase 2a clinical study results for its drug candidate RTP-026, fulfilling primary conditions toward final transaction execution and structural reorganization.